Inactive Instrument

Other languages Arrowhead Research Corp Nasdaq

Equities

US0427972098

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	Apr. 24
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	Apr. 07
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran	Mar. 25
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise	Mar. 08
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy	Mar. 08
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024	Feb. 22
Sector Update: Health Care Stocks Firmer Late Afternoon	Feb. 07
Sector Update: Health Care Stocks Advance in Afternoon Trading	Feb. 07
Sector Update: Health Care Stocks Mixed Premarket Wednesday	Feb. 07
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines	Feb. 07
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 06
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,860,019, According to a Recent SEC Filing	Feb. 02
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024	Jan. 22
Arrowhead Pharmaceuticals Insider Sold Shares Worth $292,804, According to a Recent SEC Filing	Jan. 08
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,910, According to a Recent SEC Filing	Jan. 08
Arrowhead Pharmaceuticals Shares Rise as $450 Million Underwritten Share Offering Priced	Jan. 03
Arrowhead Pharmaceuticals Prices $450 Million Underwritten Share Offering	Jan. 03
Arrowhead Pharmaceuticals Insider Sold Shares Worth $342,480, According to a Recent SEC Filing	Dec. 22
Arrowhead Pharmaceuticals' Fiscal 2023 Net Loss Widens, Revenue Falls	Nov. 29
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Arrowhead Research Corp Nasdaq

Equities

US0427972098

Other languages

Filters